Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (COMBI-v)

Clinical Trial ID NCT01597908

PubWeight™ 47.32‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01597908

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012 13.48
2 Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2014 5.65
3 Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2012 2.45
4 Strategies for modern biomarker and drug development in oncology. J Hematol Oncol 2014 1.89
5 The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma. P T 2013 1.68
6 Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 2012 1.60
7 Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int 2015 1.25
8 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
9 Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 2012 1.16
10 B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol 2013 1.14
11 The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res 2013 1.10
12 Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist 2013 1.08
13 Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc 2014 1.06
14 Targeting the RAS oncogene. Expert Opin Ther Targets 2013 1.02
15 Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol 2013 0.99
16 BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget 2014 0.92
17 New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol 2013 0.92
18 Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther 2014 0.92
19 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
20 Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol 2015 0.89
21 Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett 2015 0.88
22 Combination therapies for the treatment of advanced melanoma: a review of current evidence. Biochem Res Int 2014 0.86
23 Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res 2014 0.81
24 Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Oncotarget 2015 0.81
25 Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 2016 0.80
26 Biologics in dermatology. Pharmaceuticals (Basel) 2013 0.80
27 Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med 2014 0.80
28 New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf 2014 0.77
29 Malignant Melanoma. Healthcare (Basel) 2013 0.75
30 Evolving pharmacotherapies for the treatment of metastatic melanoma. Clin Med Insights Oncol 2013 0.75
Next 100